NYSE:PBH

Prestige Consumer Healthcare (PBH) Stock Forecast, Price & News

$58.50

+1.80 (+3.17%)

(As of 06/2/2023 ET)

Compare

Today's Range: $56.79
▼
$58.51
50-Day Range: $56.70
▼
$63.76
52-Week Range: $48.51
▼
$67.45

Volume: 295,432 shs
Average Volume: 222,395 shs
Market Capitalization: $2.91 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $79.25

Prestige Consumer Healthcare MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.60 Rating Score
Upside/Downside: 35.5% Upside
$79.25 Price Target
Short Interest: Bearish
2.44% of Float Sold Short
Dividend Strength: Weak
Based on Four Factors
Sustainability: -2.35
Upright™ Environmental Score
News Sentiment: 0.90
Based on 5 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: 6.98%
From $4.30 to $4.60 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.19 out of 5 stars

Consumer Discretionary Sector

134th out of 269 stocks

Pharmaceutical Preparations Industry

154th out of 486 stocks

3.3

Analyst's Opinion

Consensus Rating
Prestige Consumer Healthcare has received a consensus rating of Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $79.25, Prestige Consumer Healthcare has a forecasted upside of 35.5% from its current price of $58.50.
Amount of Analyst Coverage
Prestige Consumer Healthcare has only been the subject of 1 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
2.44% of the float of Prestige Consumer Healthcare has been sold short.
Short Interest Ratio / Days to Cover
Prestige Consumer Healthcare has a short interest ratio ("days to cover") of 4.8.
Change versus previous month
Short interest in Prestige Consumer Healthcare has recently increased by 5.26%, indicating that investor sentiment is decreasing significantly.

0.8

Dividend Strength

Dividend Yield
Prestige Consumer Healthcare does not currently pay a dividend.
Dividend Growth
Prestige Consumer Healthcare does not have a long track record of dividend growth.
Dividend Sustainability
Based on earnings estimates, Prestige Consumer Healthcare will have a dividend payout ratio of 41.30% next year. This indicates that Prestige Consumer Healthcare will be able to sustain or increase its dividend.

3.5

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Prestige Consumer Healthcare has received a 42.29% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Dental floss", "Topical capsaicin", "Mouthwash", "Lice shampoo", "Montelukast", and "Yeast infection medicine" products. See details.
Environmental Sustainability
The Environmental Impact score for Prestige Consumer Healthcare is -2.35.

2.7

News and Social Media Coverage

News Sentiment
Prestige Consumer Healthcare has a news sentiment score of 0.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Consumer Discretionary companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Prestige Consumer Healthcare this week, compared to 2 articles on an average week.
MarketBeat Follows
Only 1 people have added Prestige Consumer Healthcare to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Prestige Consumer Healthcare insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 1.60% of the stock of Prestige Consumer Healthcare is held by insiders.
Percentage Held by Institutions
99.98% of the stock of Prestige Consumer Healthcare is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Prestige Consumer Healthcare are expected to grow by 6.98% in the coming year, from $4.30 to $4.60 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Prestige Consumer Healthcare is -34.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Prestige Consumer Healthcare is -34.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Growth Ratio
Prestige Consumer Healthcare has a PEG Ratio of 1.65. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Prestige Consumer Healthcare has a P/B Ratio of 2.01. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Prestige Consumer Healthcare (NYSE:PBH) Stock

Prestige Consumer Healthcare, Inc. engages in the marketing, sale, and distribution of pharmaceutical drugs and consumer products. It operates through the following segments: North American OTC Healthcare and International OTC Healthcare. The North American and International OTC Healthcare segments manages the following brands: BC/Goody's, Beano, Boudreaux's Butt Paste, Chloraseptic, Clear Eyes, Compound W, Debrox, DenTek, Dramamine, Efferdent, Fess, Fleet, Gaviscon, Hydralyte, Luden's, Monistat, Nix, Pedia-Lax, and Summer's Eve. The company was founded in 1996 and is headquartered in Tarrytown, NY.

Receive PBH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Prestige Consumer Healthcare and its competitors with MarketBeat's FREE daily newsletter.

PBH Stock News Headlines

June 1, 2023 | finance.yahoo.com

Prestige Consumer Healthcare (NYSE:PBH) shareholders are still up 62% over 5 years despite pulling back 3.5% in the past week

May 31, 2023 | finance.yahoo.com

Goody’s® Introduces New “GET TO GOOD™” Marketing Campaign

June 4, 2023 | Behind the Markets (Ad)

BREAKING: Tiny biotech successfully treats blindness

There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.

May 23, 2023 | finance.yahoo.com

Dramamine® Eases Americans’ Travel Woes with ‘Ditch the Drama’ Sweepstakes Offering a Vacation to Anywhere in the World

May 14, 2023 | americanbankingnews.com

Brokerages Set Prestige Consumer Healthcare Inc. (NYSE:PBH) PT at $79.25

May 11, 2023 | americanbankingnews.com

Prestige Consumer Healthcare Inc. (NYSE:PBH) Expected to Earn Q1 2024 Earnings of $1.01 Per Share

May 10, 2023 | americanbankingnews.com

Prestige Consumer Healthcare Inc. (NYSE:PBH) to Post Q1 2024 Earnings of $1.00 Per Share, William Blair Forecasts

May 9, 2023 | msn.com

DA Davidson Reiterates Prestige Consumer Healthcare (PBH) Neutral Recommendation

June 4, 2023 | Behind the Markets (Ad)

66,000% upside on tiny biotech?

The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.

May 5, 2023 | finance.yahoo.com

Prestige Consumer Healthcare Inc. (NYSE:PBH) Shares Could Be 42% Below Their Intrinsic Value Estimate

May 4, 2023 | msn.com

Prestige Consumer (PBH) Q4 Earnings Top Estimates, Revenues Up

May 4, 2023 | finance.yahoo.com

Prestige Brands (PBH) Beats Q4 Earnings and Revenue Estimates

May 4, 2023 | finance.yahoo.com

Prestige Consumer Healthcare Inc. Reports Record Fiscal Year 2023

May 3, 2023 | americanbankingnews.com

Prestige Consumer Healthcare (PBH) Scheduled to Post Earnings on Thursday

April 25, 2023 | msn.com

J&J's $40 Billion Spinoff Has One Rival. Who Will Rule Consumer Health.

April 19, 2023 | americanbankingnews.com

Brokerages Set Prestige Consumer Healthcare Inc. (NYSE:PBH) PT at $77.40

April 18, 2023 | finance.yahoo.com

Prestige Consumer Healthcare Inc. to Release Fiscal 2023 Fourth Quarter and Year-End Earnings Results

April 13, 2023 | seekingalpha.com

Continuing To Avoid Prestige Consumer Healthcare

March 25, 2023 | americanbankingnews.com

Brokerages Set Prestige Consumer Healthcare Inc. (NYSE:PBH) Price Target at $77.40

March 20, 2023 | finance.yahoo.com

Prestige Consumer Healthcare Inc. (PBH)

March 17, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Lifecore Biomedical (LFCR), Prestige Consumer Healthcare (PBH) and Quest Diagnostics (DGX)

February 25, 2023 | finance.yahoo.com

Prestige Consumer Healthcare Inc.'s (NYSE:PBH) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

February 4, 2023 | yahoo.com

Prestige Consumer Healthcare Inc. (NYSE:PBH) Q3 2023 Earnings Call Transcript

February 2, 2023 | finance.yahoo.com

Prestige Consumer Healthcare Inc. Reports Third Quarter Results

February 2, 2023 | finance.yahoo.com

Prestige Brands (PBH) Q3 Earnings and Revenues Surpass Estimates

January 27, 2023 | nasdaq.com

Prestige Consumer (PBH) to Post Q3 Earnings: Factors to Consider

January 19, 2023 | seekingalpha.com

Prestige Consumer Healthcare: Taking My Winnings Off The Table

See More Headlines

PBH Price History

30 days | 90 days | 365 days | Advanced Chart

PBH Company Calendar

Last Earnings: 5/04/2023
Today: 6/03/2023
Next Earnings (Estimated): 8/03/2023
Fiscal Year End: 3/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Pharmaceutical preparations
Sub-Industry: Personal Products
Sector: Consumer Discretionary
Current Symbol: NYSE:PBH
CUSIP: 74112D10
CIK: 1295947
Web: www.prestigebrands.com
Phone: (914) 524-6800
Fax: 302-674-5266
Employees: 505
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $79.25
High Stock Price Forecast: $104.00
Low Stock Price Forecast: $71.00
Forecasted Upside/Downside: +35.5%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.60
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.68)
Trailing P/E Ratio: N/A
Forward P/E Ratio: 13.60
P/E Growth: 1.65
Net Income: $-82,310,000.00
Net Margins: -7.30%
Pretax Margin: -8.33%
Return on Equity: 13.38%
Return on Assets: 5.86%

Debt

Debt-to-Equity Ratio: 0.93
Current Ratio: 2.44
Quick Ratio: 1.43

Sales & Book Value

Annual Sales: $1.13 billion
Price / Sales: 2.58
Cash Flow: $5.17 per share
Price / Cash Flow: 11.32
Book Value: $29.12 per share
Price / Book: 2.01

Miscellaneous

Outstanding Shares: 49,693,000
Free Float: 48,898,000
Market Cap: $2.91 billion
Optionable: Optionable
Beta: 0.56

Key Executives

Ronald M. Lombardi
Chairman, President & Chief Executive Officer

Jeff Zerillo
Senior Vice President-Operations

Christine Sacco
Chief Financial Officer

William C. P'Pool
Secretary, Senior Vice President & General Counsel

Adel Mekhail
Executive Vice President-Marketing & Sales

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

PBH Stock - Frequently Asked Questions

Should I buy or sell Prestige Consumer Healthcare stock right now?: 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Prestige Consumer Healthcare in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PBH shares.
View PBH analyst ratings or view top-rated stocks.
What is Prestige Consumer Healthcare's stock price forecast for 2023?: 5 Wall Street analysts have issued 12 month target prices for Prestige Consumer Healthcare's stock. Their PBH share price forecasts range from $71.00 to $104.00. On average, they predict the company's stock price to reach $79.25 in the next twelve months. This suggests a possible upside of 35.5% from the stock's current price.
View analysts price targets for PBH or view top-rated stocks among Wall Street analysts.
How have PBH shares performed in 2023?: Prestige Consumer Healthcare's stock was trading at $62.60 at the beginning of 2023. Since then, PBH shares have decreased by 6.5% and is now trading at $58.50.
View the best growth stocks for 2023 here.
When is Prestige Consumer Healthcare's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our PBH earnings forecast.
How were Prestige Consumer Healthcare's earnings last quarter?: Prestige Consumer Healthcare Inc. (NYSE:PBH) announced its earnings results on Thursday, May, 4th. The company reported $1.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.04 by $0.03. The business earned $285.90 million during the quarter, compared to the consensus estimate of $280.58 million. Prestige Consumer Healthcare had a positive trailing twelve-month return on equity of 13.38% and a negative net margin of 7.30%. The firm's revenue was up 7.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.91 earnings per share.
What ETFs hold Prestige Consumer Healthcare's stock?: ETFs with the largest weight of Prestige Consumer Healthcare (NYSE:PBH) stock in their portfolio include Invesco Dynamic Pharmaceuticals ETF (PJP), Invesco S&P SmallCap Health Care ETF (PSCH), Schwab Ariel ESG ETF (SAEF), SPDR S&P Pharmaceuticals ETF (XPH), Global X Health & Wellness ETF (BFIT), ETC 6 Meridian Small Cap Equity ETF (SIXS), iShares U.S. Pharmaceuticals ETF (IHE) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).
Is Prestige Consumer Healthcare a good dividend stock?: Prestige Consumer Healthcare (NYSE:PBH) pays an annual dividend of $1.90 per share and currently has a dividend yield of 0.00%.
What guidance has Prestige Consumer Healthcare issued on next quarter's earnings?: Prestige Consumer Healthcare updated its FY 2023 earnings guidance on Thursday, May, 4th. The company provided earnings per share (EPS) guidance of $4.27-$4.32 for the period, compared to the consensus earnings per share estimate of $4.18. The company issued revenue guidance of $1.14 billion-$1.14 billion, compared to the consensus revenue estimate of $1.12 billion.

What is Ronald M. Lombardi's approval rating as Prestige Consumer Healthcare's CEO?: 8 employees have rated Prestige Consumer Healthcare Chief Executive Officer Ronald M. Lombardi on Glassdoor.com. Ronald M. Lombardi has an approval rating of 61% among the company's employees. This puts Ronald M. Lombardi in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Prestige Consumer Healthcare own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Prestige Consumer Healthcare investors own include Pfizer (PFE), AbbVie (ABBV), Gilead Sciences (GILD), AT&T (T), Intel (INTC), ONEOK (OKE), Wells Fargo & Company (WFC), International Business Machines (IBM), Micron Technology (MU) and Teva Pharmaceutical Industries (TEVA).
What is Prestige Consumer Healthcare's stock symbol?: Prestige Consumer Healthcare trades on the New York Stock Exchange (NYSE) under the ticker symbol "PBH."
Who are Prestige Consumer Healthcare's major shareholders?: Prestige Consumer Healthcare's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (18.35%), Dimensional Fund Advisors LP (7.40%), Macquarie Group Ltd. (5.54%), State Street Corp (3.85%), FMR LLC (2.14%) and Geode Capital Management LLC (2.07%). Insiders that own company stock include Mary Beth Fritz and Ronald M Lombardi.
View institutional ownership trends.
How do I buy shares of Prestige Consumer Healthcare?: Shares of PBH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Prestige Consumer Healthcare's stock price today?: One share of PBH stock can currently be purchased for approximately $58.50.
How much money does Prestige Consumer Healthcare make?: Prestige Consumer Healthcare (NYSE:PBH) has a market capitalization of $2.91 billion and generates $1.13 billion in revenue each year. The company earns $-82,310,000.00 in net income (profit) each year or ($1.68) on an earnings per share basis.
How many employees does Prestige Consumer Healthcare have?: The company employs 505 workers across the globe.
How can I contact Prestige Consumer Healthcare?: Prestige Consumer Healthcare's mailing address is 660 WHITE PLAINS ROAD SUITE 250, TARRYTOWN NY, 10591. The official website for the company is www.prestigebrands.com. The company can be reached via phone at (914) 524-6800, via email at irinquiries@prestigebrands.com, or via fax at 302-674-5266.

This page (NYSE:PBH) was last updated on 6/4/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial